These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 32339392

  • 1. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
    Wiese MD, Hopkins AM, King C, Wechalekar MD, Lee A, Spargo L, Metcalf R, McWilliams L, Hill C, Cleland LG, Proudman SM.
    Arthritis Care Res (Hoboken); 2021 Jul; 73(7):983-989. PubMed ID: 32339392
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels.
    Fajardo-Robledo NS, Jacobo-Cuevas H, Perez-Guerrero EE, Corona-Sanchez EG, Saldaña-Cruz AM, Romero-Tejeda EM, Rodriguez-Jimenez NA, Totsuka-Sutto SE, Lopez-Roa RI, Ponce-Guarneros JM, Alcaraz-Lopez MF, Cerpa-Cruz S, Muñoz-Valle JF, Cardona-Muñoz EG, Gonzalez-Lopez L, Gamez-Nava JI, Research Group for Factors Related to Therapeutic Outcomes in Autoimmune Diseases.
    Sci Rep; 2022 Feb 03; 12(1):1877. PubMed ID: 35115601
    [Abstract] [Full Text] [Related]

  • 3. Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.
    Hopkins AM, Wiese MD, Proudman SM, O'Doherty CE, Upton RN, Foster DJ.
    Br J Clin Pharmacol; 2016 Jan 03; 81(1):113-23. PubMed ID: 26331989
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
    Kaur H, Sarma P, Bhattacharyya A, Sharma S, Chhimpa N, Prajapat M, Prakash A, Kumar S, Singh A, Singh R, Avti P, Thota P, Medhi B.
    Eur J Pharmacol; 2021 Sep 05; 906():174233. PubMed ID: 34111397
    [Abstract] [Full Text] [Related]

  • 5. Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects.
    Yao X, Wu Y, Jiang J, Hu P, Liu D, Chen X.
    Clin Drug Investig; 2019 Jul 05; 39(7):643-651. PubMed ID: 31016613
    [Abstract] [Full Text] [Related]

  • 6. LC-MS/MS Method for the Quantification of the Leflunomide Metabolite, Teriflunomide, in Human Serum/Plasma.
    Rule GS, Rockwood AL, Johnson-Davis KL.
    Methods Mol Biol; 2019 Jul 05; 1872():75-83. PubMed ID: 30350281
    [Abstract] [Full Text] [Related]

  • 7. Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis.
    O'Doherty C, Schnabl M, Spargo L, Cleland LG, James M, Proudman SM, Wiese MD.
    Pharmacogenomics; 2012 Sep 05; 13(12):1427-34. PubMed ID: 22966891
    [Abstract] [Full Text] [Related]

  • 8. The Mitochondria-Independent Cytotoxic Effect of Leflunomide on RPMI-8226 Multiple Myeloma Cell Line.
    Adamczuk G, Humeniuk E, Iwan M, Natorska-Chomicka D, Adamczuk K, Korga-Plewko A.
    Molecules; 2021 Sep 17; 26(18):. PubMed ID: 34577124
    [Abstract] [Full Text] [Related]

  • 9. Development of a simple HPLC-MS/MS method to simultaneously determine teriflunomide and its metabolite in human plasma and urine: Application to clinical pharmacokinetic study of teriflunomide sodium and leflunomide.
    Yao X, Liu Y, Song L, Jiang J, Xiao F, Liu D, Hu P.
    Biomed Chromatogr; 2019 Mar 17; 33(3):e4420. PubMed ID: 30362147
    [Abstract] [Full Text] [Related]

  • 10. Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors.
    Pontikos MA, Leija C, Zhao Z, Wang X, Kilgore J, Tornesi B, Adenmatten N, Phillips MA, Williams NS.
    Biochem Pharmacol; 2022 Oct 17; 204():115237. PubMed ID: 36055381
    [Abstract] [Full Text] [Related]

  • 11. Effect of the Intramolecular Hydrogen Bond on the Active Metabolite Analogs of Leflunomide for Blocking the Plasmodium falciparum Dihydroorotate Dehydrogenase Enzyme: QTAIM, NBO, and Docking Study.
    Heidarian R, Zahedi-Tabrizi M.
    Curr Comput Aided Drug Des; 2021 Oct 17; 17(3):480-491. PubMed ID: 32459610
    [Abstract] [Full Text] [Related]

  • 12. Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study.
    Balagué C, Pont M, Prats N, Godessart N.
    Br J Pharmacol; 2012 Jun 17; 166(4):1320-32. PubMed ID: 22229697
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic drug monitoring of teriflunomide: do plasma concentrations predict response to leflunomide in patients with rheumatoid arthritis?
    Rawdha T, Aicha BT, Lobna BA, Issam S, Mouna BS, Olfa S, Selma B, Takoua BB, Kawther BA, Leila M, Hana S, Ines M, Leila A.
    Drug Metab Pers Ther; 2023 Mar 01; 38(1):79-85. PubMed ID: 35998916
    [Abstract] [Full Text] [Related]

  • 14. Quantitation of Teriflunomide in Human Serum/Plasma Across a 40,000-Fold Concentration Range by LC/MS/MS.
    Rule GS, Rockwood AL, Johnson-Davis KL.
    Methods Mol Biol; 2016 Mar 01; 1383():195-203. PubMed ID: 26660188
    [Abstract] [Full Text] [Related]

  • 15. Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model.
    Bae J, Park JW.
    Drug Dev Ind Pharm; 2016 Mar 01; 42(2):254-62. PubMed ID: 26006334
    [Abstract] [Full Text] [Related]

  • 16. A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus.
    Yao X, Wu Y, Jiang J, Chen X, Liu D, Hu P.
    Eur J Pharm Sci; 2019 Aug 01; 136():104942. PubMed ID: 31154006
    [Abstract] [Full Text] [Related]

  • 17. On the interactions of leflunomide and teriflunomide within receptor cavity--NMR studies and energy calculations.
    Kujawski J, Bernard MK, Jodłowska E, Czaja K, Drabińska B.
    J Mol Model; 2015 May 01; 21(5):105. PubMed ID: 25851105
    [Abstract] [Full Text] [Related]

  • 18. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide.
    Pawlik A, Herczynska M, Kurzawski M, Safranow K, Dziedziejko V, Drozdzik M.
    Pharmacogenomics; 2009 Feb 01; 10(2):303-9. PubMed ID: 19207032
    [Abstract] [Full Text] [Related]

  • 19. Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in vitro models.
    Jones SW, Penman SL, French NS, Park BK, Chadwick AE.
    Toxicol In Vitro; 2021 Apr 01; 72():105096. PubMed ID: 33460737
    [Abstract] [Full Text] [Related]

  • 20. Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study.
    Bergner R, Peters L, Schmitt V, Löffler C.
    Clin Rheumatol; 2013 Feb 01; 32(2):267-70. PubMed ID: 23179005
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.